Literature DB >> 29768067

The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic.

Thinzar M Lwin1, Robert M Hoffman1,2, Michael Bouvet1,3.   

Abstract

INTRODUCTION: Surgeons face major challenges in achieving curative R0 resection for pancreatic cancers. When the lesion is localized, they must appropriately visualize the tumor, determine appropriate resection margins, and ensure complete tumor clearance. Real-time surgical navigation using fluorescence-guidance has enhanced the ability of surgeons to see the tumor and has the potential to assist in achieving more oncologically complete resections. When there is metastatic disease, fluorescence enhancement can help detect these lesions and prevent unnecessary and futile surgeries. Areas covered: This article reviews different approaches for delivery of a fluorescence signal, their pre-clinical and clinical developments for fluorescence guided surgery, the advantages/challenges of each, and their potential for advancements in the future. Expert commentary: A variety of molecular imaging techniques are available for delivering tumor-specific fluorescence signals. Significant advancements have been made in the past 10 years due to the large body of literature on targeted therapies and this has translated into rapid developments of tumor-specific probes.

Entities:  

Keywords:  Pancreatic cancer; antibodies; fluorescence-guided surgery; fluorophores; mouse models

Mesh:

Year:  2018        PMID: 29768067      PMCID: PMC6298876          DOI: 10.1080/14737140.2018.1477593

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  121 in total

1.  Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study.

Authors:  Niels J Harlaar; Marjory Koller; Steven J de Jongh; Barbara L van Leeuwen; Patrick H Hemmer; Schelto Kruijff; Robert J van Ginkel; Lukas B Been; Johannes S de Jong; Gursah Kats-Ugurlu; Matthijs D Linssen; Annelies Jorritsma-Smit; Marleen van Oosten; Wouter B Nagengast; Vasilis Ntziachristos; Gooitzen M van Dam
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-09-17

2.  Near-infrared fluorescence imaging in patients undergoing pancreaticoduodenectomy.

Authors:  M Hutteman; J R van der Vorst; J S D Mieog; B A Bonsing; H H Hartgrink; P J K Kuppen; C W G M Löwik; J V Frangioni; C J H van de Velde; A L Vahrmeijer
Journal:  Eur Surg Res       Date:  2011-06-30       Impact factor: 1.745

3.  Characterizing the Utility and Limitations of Repurposing an Open-Field Optical Imaging Device for Fluorescence-Guided Surgery in Head and Neck Cancer Patients.

Authors:  Lindsay S Moore; Eben L Rosenthal; Thomas K Chung; Esther de Boer; Neel Patel; Andrew C Prince; Melissa L Korb; Erika M Walsh; E Scott Young; Todd M Stevens; Kirk P Withrow; Anthony B Morlandt; Joshua S Richman; William R Carroll; Kurt R Zinn; Jason M Warram
Journal:  J Nucl Med       Date:  2016-09-01       Impact factor: 10.057

4.  Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.

Authors:  George Hajjar; Robert M Sharkey; Jack Burton; Chu-Hui Zhang; Dion Yeldell; Alexander Matthies; Abass Alavi; Michele J Losman; Arnold Brenner; David M Goldenberg
Journal:  Clin Colorectal Cancer       Date:  2002-05       Impact factor: 4.481

5.  Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model resistant to neoadjuvant chemotherapy (NAC).

Authors:  Yukihiko Hiroshima; Ali Maawy; Yong Zhang; Takashi Murakami; Masashi Momiyama; Ryutaro Mori; Ryusei Matsuyama; Takashi Chishima; Kuniya Tanaka; Yasushi Ichikawa; Itaru Endo; Robert M Hoffman; Michael Bouvet
Journal:  Pancreatology       Date:  2015-03-07       Impact factor: 3.996

Review 6.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.

Authors:  H Maeda; J Wu; T Sawa; Y Matsumura; K Hori
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

7.  Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis.

Authors:  Ryo Hosotani; Michiya Kawaguchi; Toshihiko Masui; Takatomo Koshiba; Jyun Ida; Koji Fujimoto; Michihiko Wada; Ryuichiro Doi; Masayuki Imamura
Journal:  Pancreas       Date:  2002-08       Impact factor: 3.327

8.  Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease.

Authors:  A von Rosen; S Linder; U Harmenberg; S Pegert
Journal:  Pancreas       Date:  1993-03       Impact factor: 3.327

9.  The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.

Authors:  Paula Ghaneh; Jorg Kleeff; Christopher M Halloran; Michael Raraty; Richard Jackson; James Melling; Owain Jones; Daniel H Palmer; Trevor F Cox; Chloe J Smith; Derek A O'Reilly; Jakob R Izbicki; Andrew G Scarfe; Juan W Valle; Alexander C McDonald; Ross Carter; Niall C Tebbutt; David Goldstein; Robert Padbury; Jennifer Shannon; Christos Dervenis; Bengt Glimelius; Mark Deakin; Alan Anthoney; Markus M Lerch; Julia Mayerle; Attila Oláh; Charlotte L Rawcliffe; Fiona Campbell; Oliver Strobel; Markus W Büchler; John P Neoptolemos
Journal:  Ann Surg       Date:  2019-03       Impact factor: 12.969

10.  The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters.

Authors:  George Giannopoulos; Kitty Pavlakis; Aikaterini Parasi; Nikolaos Kavatzas; Dina Tiniakos; Antigoni Karakosta; Nikolaos Tzanakis; George Peros
Journal:  Anticancer Res       Date:  2008 May-Jun       Impact factor: 2.480

View more
  10 in total

1.  Engineering of a novel subnanomolar affinity fibronectin III domain binder targeting human programmed death-ligand 1.

Authors:  Sindhuja Ramakrishnan; Arutselvan Natarajan; Carmel T Chan; Paramjyot Singh Panesar; Sanjiv S Gambhir
Journal:  Protein Eng Des Sel       Date:  2019-12-31       Impact factor: 1.650

2.  Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer.

Authors:  Madeline T Olson; Nicholas E Wojtynek; Geoffrey A Talmon; Thomas C Caffrey; Prakash Radhakrishnan; Quan P Ly; Michael A Hollingsworth; Aaron M Mohs
Journal:  Mol Cancer Ther       Date:  2020-05-13       Impact factor: 6.261

3.  ASO Author Reflections: Fluorescent Anti-CEA IR800 for Tumor Labeling.

Authors:  Thinzar M Lwin; Michael Bouvet
Journal:  Ann Surg Oncol       Date:  2018-10-15       Impact factor: 5.344

4.  Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft.

Authors:  Michael A Turner; Hannah M Hollandsworth; Hiroto Nishino; Siamak Amirfakhri; Thinzar M Lwin; Andrew M Lowy; Sukhwinder Kaur; Gopalakrishnan Natarajan; Kavita Mallya; Robert M Hoffman; Surinder K Batra; Michael Bouvet
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

5.  Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.

Authors:  Guolan Lu; Nynke S van den Berg; Brock A Martin; Naoki Nishio; Zachary P Hart; Stan van Keulen; Shayan Fakurnejad; Stefania U Chirita; Roan C Raymundo; Grace Yi; Quan Zhou; George A Fisher; Eben L Rosenthal; George A Poultsides
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05-14

6.  Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer.

Authors:  Thinzar M Lwin; Sophie Hernot; Hannah Hollandsworth; Siamak Amirfakhri; Filemoni Filemoni; Pieterjan Debie; Robert M Hoffman; Michael Bouvet
Journal:  Surgery       Date:  2020-05-04       Impact factor: 3.982

Review 7.  Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer.

Authors:  V M Baart; R D Houvast; L F de Geus-Oei; P H A Quax; P J K Kuppen; A L Vahrmeijer; C F M Sier
Journal:  EJNMMI Res       Date:  2020-07-28       Impact factor: 3.138

8.  Strong Dependence between Tryptophan-Related Fluorescence of Urine and Malignant Melanoma.

Authors:  Anna Birková; Marcela Valko-Rokytovská; Beáta Hubková; Marianna Zábavníková; Mária Mareková
Journal:  Int J Mol Sci       Date:  2021-02-13       Impact factor: 5.923

Review 9.  Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.

Authors:  Martijn A van Dam; Floris A Vuijk; Judith A Stibbe; Ruben D Houvast; Saskia A C Luelmo; Stijn Crobach; Shirin Shahbazi Feshtali; Lioe-Fee de Geus-Oei; Bert A Bonsing; Cornelis F M Sier; Peter J K Kuppen; Rutger-Jan Swijnenburg; Albert D Windhorst; Jacobus Burggraaf; Alexander L Vahrmeijer; J Sven D Mieog
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

10.  An activated excretion-retarded tumor imaging strategy towards metabolic organs.

Authors:  Da-Yong Hou; Man-Di Wang; Xing-Jie Hu; Zhi-Jia Wang; Ni-Yuan Zhang; Gan-Tian Lv; Jia-Qi Wang; Xiu-Hai Wu; Lu Wang; Hao Wang; Wanhai Xu
Journal:  Bioact Mater       Date:  2021-12-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.